Brief Report: Stavudine but not Didanosine as Part of HAART Contributes to Peripheral Lipoatrophy: A Substudy from the Antiretroviral Regimen Evaluation Study (ARES)

REFERENCES

• Grinspoon S, Carr A. Cardiovascular risk and body-fat ab-normalities in HIV-infected adults. N Engl J Med. 2005;352: 48–62.
   PubMed Web of Science ®Google Scholar
• Fliers E, Sauerwein HP, Romijn JA, et al. HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet. 2003;362:1758–1760.
   PubMed Web of Science ®Google Scholar
• Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005;40:121–131.
   PubMed Web of Science ®Google Scholar
• Melia! SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309–1316.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse tran-scriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 200115: 847–855.
   Google Scholar
• Nolan D, Hammond E, James I, McKinnon E, Melia! S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antiviral Ther 2003;8:617–626.
   Google Scholar
• Lichtenstein KA. Redefining lipodystrophy syndrome. Risks and impact on clinical decision making. J Acquir Im-mune Defic Syndr 2005;39:395–400.
   PubMed Web of Science ®Google Scholar
• Dube MP. HIV-associated lipoatrophy: what are the kinder, gentler agents? Clin Infect Dis. 2006;42:281–282.
   PubMed Web of Science ®Google Scholar
• Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoat-rophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002;16:2447–2454.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Casula M, Weverling GJ, et al. Prevalence of lipoatrophy and mitochondria! DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allo-cated to zidovudine-or stavudine-based therapy. Antiviral Ther 2004;9:385–393.
   PubMed Web of Science ®Google Scholar
• Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807–1818.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Im-mune Defic Syndr 2006;41:590–597.
   PubMed Web of Science ®Google Scholar
• Mallon PWG, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretoviral therapy on body composition in HIV-1 infected men starting therapy. AIDS. 2003;17:971–979.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191–201.
   PubMed Web of Science ®Google Scholar
• Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002288: 207–215.
   Google Scholar
• John M, McKinnon EJ, James IR, et al. Randomized, con-trolled, 48 week study of switching stavudine and/or pro-tease inhibitors to Combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003;33:29–33.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Ward DJ, Hessenthaler SM, et al. Im-provement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263–270.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the man-agement of dyslipidemia and peripheral lipoatrophy. J Ac-quir Immune Defic Syndr 2003;33: 22–28.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Sabin CA, Cartledge J, et al. A randomized com-parative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043–2050.
   PubMed Web of Science ®Google Scholar
• Chene G, Angelini E, Cotte L, et al. Role of long-term nu-cleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficency virus-infected pa-tients. Clin Infect Dis. 2002;34:649–657.
   PubMed Web of Science ®Google Scholar
• Shlay JC, Visnegarwala F, Bartsch G, et al. Body composi-tion and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 2005;38:147–155.
   PubMed Web of Science ®Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat dis-tribution evaluated by computed tomography and meta-bolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 2000;14: 37–49.
   PubMed Web of Science ®Google Scholar
• Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA. 2004;292:180–189.
   PubMed Web of Science ®Google Scholar
• Lowe SH, Wensing AMJ, Hassink EAM, et al. Compari-son of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiret-roviral Regimen Evaluation Study (ARES). HIV Clin Trials. 2005;6:235–245.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 Recommendations of the Inter-national AIDS Society-USA Panel. JAMA. 2006;296:827–843.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents - A working group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (October 10,2006). Available at: http://AIDSinfo.nih.gov.
   Google Scholar
• Gallant J, DeJesus E, Arribas JR, et al. Tenofovir Df, em-tricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354: 251–260.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatro-phy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2006 [Epub ahead of print].
   Web of Science ®Google Scholar
• Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each admin-istered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2006;42:273–280.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivi-ral Ther 2001;6:249–253.
   PubMed Web of Science ®Google Scholar